After Mazen discusses how he became engaged in studying cost effectiveness in screening diabetes patients for NASH, he offers a 30,000-foot view of his findings and shares thoughts on what he plans to study next.
Stephen Harrison and Louise Campbell comment on the exceptional value of his work, after which Roger Green joins Louise in asking how COVID-19 might shape future cost effectiveness estimates.
This ground-breaking work has the potential to expand and redefine the role of population testing in the coming Fatty Liver pandemic.
